Delivery Order SPE2DB24D1205-SPE2DB25FCZSG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 150 mg tablets (30-count units) with a ceiling value of $1,178.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The contract was competitively awarded without set-aside designation and is scheduled for...
- The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 5, 2025, by the Defense Logistics Agency for the supply of Xcopri 100 mg tablets (30-count package) with a ceiling value of $4,846.14. This competitively awarded, firm fixed-price delivery order is set to be completed by August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $2,357.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xcopri 25 mg tablets (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 6, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contract involves no set-aside designation and identifies Conshohocken, Pennsylvania, as the place of performance,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $2,070.10. This competitive award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, indicating it...
- The Defense Logistics Agency awarded a $2,232.99 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 200 mg on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery to support federal medical procurement needs, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $2,569.42 on July 28, 2025, for Xcopri 50 mg tablets (30-count supply). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract under the company's existing pharmaceutical supply agreements with DLA. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZSGDelivery Order
The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems. The delivery will be performed at the company's Conshohocken facility. This delivery order is part of AmerisourceBergen's comprehensive pharmaceutical supply relationship with the Defense Logistics Agency, which covers a broad spectrum of medications and medical supplies across multiple therapeutic domains. The company maintains established capabilities in fulfilling federal medical procurement requirements through competitive, non-set-aside awards, demonstrating its ability to support critical healthcare needs across the Department of Defense. Xcopri (cenobamate) is an antiepileptic medication used in treating partial-onset seizures, reflecting the vendor's role in supplying specialized neurological pharmaceuticals to federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/19/25 |